Prognostic Factors in Glioma Survival Outcomes

Survival outcomes in patients with gliomas are determined by a constellation of clinical, molecular and histopathological factors. Clinically, age at diagnosis and functional performance—often quantified by the Karnofsky Performance Score—remain among the strongest predictors of overall survival. Surgical factors, notably the extent of resection, influence residual tumour burden and subsequent response to adjuvant therapies. On the molecular front, isocitrate dehydrogenase (IDH) mutation status distinguishes biologically less aggressive tumours with longer median survival, while O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation predicts improved response to alkylating chemotherapy. Histopathological indices, including the Ki-67 labelling index and microvascular density, reflect proliferative activity and neoangiogenesis, respectively. Emerging studies integrate radiomic and genomic data to refine prognostic models, capturing tumour heterogeneity and informing personalised treatment strategies. Collectively, these prognostic factors guide risk stratification, optimisation of therapeutic intensity and the design of novel clinical trials.

Research from Nature Portfolio

Recent work has refined the prognostic evaluation of proliferative markers by employing automated digital pathology to exclude non-tumour cell proliferation. In a well-annotated cohort of glioblastoma patients, automated image analysis quantified intratumoural Ki-67 labelling more precisely than manual scoring. While Ki-67 index increased with histological grade, it showed no independent association with survival when accounting for promoter methylation status and IDH mutation. This highlights the need for caution in over-interpreting proliferation indices in isolation and underlines the value of multiplexed digital methods to distinguish tumour-specific from stromal proliferation.

Prognostic Factors in Glioma Survival Outcomes publication trend

The graph below shows the total number of articles in prognostic factors in glioma survival outcomes across all publications each year (not limited to Nature Index journals).

Technical terms

Ki-67 labelling index: The percentage of tumour nuclei staining positive for Ki-67, indicating cell proliferation.

MGMT promoter methylation: Epigenetic silencing of the MGMT DNA repair gene, predictive of sensitivity to alkylating chemotherapy.

IDH mutation: A genetic alteration in isocitrate dehydrogenase enzymes, associated with improved prognosis in gliomas.

Karnofsky Performance Score (KPS): A scale (0–100) assessing a patient’s functional status and ability to carry out daily activities.

References

1. Evaluation of Microvascular Density in Glioblastomas in Relation to p53 and Ki67 Immunoexpression. International Journal of Molecular Sciences (2024).
2. Survival Outcomes and Prognostic Factors in Glioblastoma. Cancers (2022).
3. Association of MGMT Promoter and Enhancer Methylation with Genetic Variants, Clinical Parameters, and Demographic Characteristics in Glioblastoma. Cancers (2023).
4. Prognostic role of Ki-67 in glioblastomas excluding contribution from non-neoplastic cells. Scientific Reports (2021).
5. Prognostic Factors of Survival in Glioblastoma Multiforme Patients—A Retrospective Study. Diagnostics (2022).
6. Low expression of Ki-67/MIB-1 labeling index in IDH wild type glioblastoma predicts prolonged survival independently by MGMT methylation status. Journal of Neuro-Oncology (2023).